कोशिश गोल्ड - मुक्त
Next-generation surgical robotics stand poised for global revolution
Bio Spectrum
|August 2025
The adoption of robot-assisted surgery has increased significantly in the past decade as opportunities for performing minimally invasive procedures have multiplied.

Robotic-assisted interventions as a proportion of the total number of surgeries have witnessed strong uptake among hospitals, especially in both developed and developing countries such as the United States, Japan, South Korea, China and India. Surgical robotic platforms facilitate more precise surgeries and improve the repeatability of procedural movements. These benefits support faster recovery and better outcomes for patients, which has helped drive their adoption among healthcare providers.
In spite of the many advantages, surgical robotic platforms have drawbacks. Legacy surgical robots involve a large setup that consumes significant space in the operating room. The platforms are not mobile and cannot be transferred from one room to another after installation. Moreover, the instrument setup and positioning of conventional robotic surgical arms before the procedure require considerable effort, which subsequently increases the total operation time frame. The use of rigid instruments in these traditional surgical robotic platforms becomes extremely challenging in nonlinear pathways and makes it difficult to reach anatomical areas such as the brain in a minimally invasive fashion. This has spurred the development of agile and state-of-the-art next-generation surgical robotic technology platforms, which have been built with unique designs, advanced instrumentation, analytics and visualisation technologies that address the limitations of conventional surgical robotic systems.
Small footprint: Next-generation surgical robotic technology platforms have a smaller footprint that makes them easily accommodated in operating rooms without taking up much space. Moreover, these mobile platforms can be rapidly deployed in various operating rooms to facilitate higher utilisation.
यह कहानी Bio Spectrum के August 2025 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 9,500 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
Bio Spectrum से और कहानियाँ

Bio Spectrum
WHO certifies Suriname malaria-free
Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).
1 min
August 2025

Bio Spectrum
Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation
Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.
1 min
August 2025
Bio Spectrum
Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab
Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.
1 min
August 2025
Bio Spectrum
Illumina buys SomaLogic for $425 M to accelerate proteomics business
Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.
1 min
August 2025

Bio Spectrum
Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26
Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.
1 min
August 2025
Bio Spectrum
WHO highlights risks associated with use of semaglutide medicines
The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.
1 min
August 2025

Bio Spectrum
Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin
Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.
1 min
August 2025

Bio Spectrum
AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru
AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.
1 min
August 2025

Bio Spectrum
Novo Nordisk launches injectable Semaglutide for weight management in India
Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.
1 min
August 2025

Bio Spectrum
Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?
India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.
12 mins
August 2025
Listen
Translate
Change font size